TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Tolerability of Magnetic Seizure Therapy (MST) as an Alternative to Electroconvulsive Therapy (ECT) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder
Brief Summary: Electroconvulsive therapy (ECT) has unparalleled efficacy in treating severe depression, and is also useful in treatment-refractory cases of schizophrenia and obsessive compulsive disorder (OCD). However, its use is limited by significant adverse effects on memory and cognition. In addition, ECT cannot be precisely targeted, since it relies on unpredictable pathways of electrical conduction through the brain. Magnetic seizure therapy (MST) is currently under investigation as a targetable, cognition-sparing alternative to ECT. MST uses magnetic fields rather than electrical stimuli for seizure induction, dramatically reducing the passage of induced current through undesired brain regions. 10 years of experimental studies have established the safety of MST in animal and human subjects. This pilot study will investigate whether MST has similar efficacy to ECT, with fewer cognitive side effects, in patients with severe depression, schizophrenia, and OCD.


Options:
A: Arm Label: Magnetic Seizure Therapy (MST); Type: EXPERIMENTAL; Interventions: Device: Tonica MagPro MST | Arm Label: Electroconvulsive Therapy (ECT); Type: ACTIVE_COMPARATOR; Interventions: Device: Thymatron | Intervention Type: DEVICE; Name: Thymatron; Assigned to Arm(s): Electroconvulsive Therapy (ECT) | Intervention Type: DEVICE; Name: Tonica MagPro MST; Assigned to Arm(s): Magnetic Seizure Therapy (MST)
B: Arm Label: Magnetic Seizure Therapy; Type: EXPERIMENTAL; Interventions: Device: Magnetic Seizure Therapy (MagPro MST) | Intervention Type: DEVICE; Name: Magnetic Seizure Therapy (MagPro MST); Assigned to Arm(s): Magnetic Seizure Therapy
C: Arm Label: Magnetic seizure therapy; Type: EXPERIMENTAL; Interventions: Device: Magnetic seizure therapy | Arm Label: Electroconvulsive therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Electroconvulsive therapy | Intervention Type: DEVICE; Name: Magnetic seizure therapy; Assigned to Arm(s): Magnetic seizure therapy | Intervention Type: DEVICE; Name: Electroconvulsive therapy; Assigned to Arm(s): Electroconvulsive therapy
D: Arm Label: Magnetic Seizure Therapy (MST); Type: EXPERIMENTAL; Interventions: Device: MagVenture MagPro MST | Arm Label: RUL ECT; Type: ACTIVE_COMPARATOR; Interventions: Biological: RUL ECT | Intervention Type: DEVICE; Name: MagVenture MagPro MST; Assigned to Arm(s): Magnetic Seizure Therapy (MST) | Intervention Type: BIOLOGICAL; Name: RUL ECT; Assigned to Arm(s): RUL ECT

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Antioxidants Supplementation on Muscular Function of Patients Affected by Facioscapulohumeral Dystrophy (FSHD)
Brief Summary: On the basis of published data and the investigators' results indicating that oxidative stress may contribute to the peripheral skeletal muscle dysfunction in patients with FSHD, the investigators propose a study to test whether or not an antioxidant supplementation has a therapeutic interest for patients with FSHD. Their results have important implications for the successful implementation of rational antioxidant therapy in FSHD in which cell loss could be linked to oxidative stress.


Options:
A: Arm Label: n-acetylcysteine/placebo supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: n-acetylcysteine supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: n-acetylcysteine supplementation; Assigned to Arm(s): n-acetylcysteine/placebo supplementation
B: Arm Label: 9 elite weightlifters; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Natural Pomegranate Juice | Arm Label: 9elite weightlifters; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo Juice | Intervention Type: DIETARY_SUPPLEMENT; Name: Natural Pomegranate Juice; Assigned to Arm(s): 9 elite weightlifters | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo Juice; Assigned to Arm(s): 9elite weightlifters
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C, Vitamin E | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Antioxidant treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C, Vitamin E; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Antioxidant treatment; Assigned to Arm(s): 2
D: Arm Label: vitamins minerals; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Taking of blood, Dietary Supplement: needle biopsy of the vastus lateralis muscle, Dietary Supplement: Vit C Vit E Zn Se | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Taking of blood, Dietary Supplement: needle biopsy of the vastus lateralis muscle, Dietary Supplement: Placebo Vit E Placebo Vit C Zn Se | Intervention Type: PROCEDURE; Name: Taking of blood; Assigned to Arm(s): Placebo, vitamins minerals | Intervention Type: DIETARY_SUPPLEMENT; Name: needle biopsy of the vastus lateralis muscle; Assigned to Arm(s): Placebo, vitamins minerals | Intervention Type: DIETARY_SUPPLEMENT; Name: Vit C Vit E Zn Se; Assigned to Arm(s): vitamins minerals | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo Vit E Placebo Vit C Zn Se; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Open-Label Active-Comparator (Epoetin Alfa) Dose-Ranging Safety and Exploratory Efficacy Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis (HD)
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of FG-4592 in maintaining and/or correcting hemoglobin (Hb) given to subjects with End Stage Renal Disease (ESRD) on maintenance hemodialysis and receiving epoetin alfa.


Options:
A: Arm Label: FG-4592; Type: EXPERIMENTAL; Interventions: Drug: FG-4592 | Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: FG-4592; Assigned to Arm(s): FG-4592 | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin alfa
B: Arm Label: Darbepoetin Alfa Injection; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa | Arm Label: Desidustat oral tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desidustat Oral Tablet | Intervention Type: DRUG; Name: Desidustat Oral Tablet; Assigned to Arm(s): Desidustat oral tablet | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Darbepoetin Alfa Injection
C: Arm Label: Molidustat (BAY85-3934); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934) | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat (BAY85-3934)
D: Arm Label: Vadadustat; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Single Blinded, Controlled, Multi Center Phase 4 Study for Induction of Remission in Active Pediatric Crohn's Disease, Using 2 Months Antibiotic Course of Azithromycin Combined With Metronidazole vs. Metronidazole Alone.
Brief Summary: The purpose of this study is to evaluate effectiveness of 2 months antibiotic course of Azithromycin combined with Metronidazole compared with 2 months antibiotic course of Metronidazole alone.


Options:
A: Arm Label: Antibiotics in addition to steroids; Type: EXPERIMENTAL; Interventions: Drug: AB (antibiotics) | Arm Label: Steroids only; Type: ACTIVE_COMPARATOR; Interventions: Drug: CS (corticosteroids) Only | Arm Label: Open arm; Type: OTHER; Interventions: Drug: AB (antibiotics), Drug: CS (corticosteroids) Only | Intervention Type: DRUG; Name: AB (antibiotics); Assigned to Arm(s): Antibiotics in addition to steroids, Open arm | Intervention Type: DRUG; Name: CS (corticosteroids) Only; Assigned to Arm(s): Open arm, Steroids only
B: Arm Label: Azithromycin + Metronidazole; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin + Metronidazole | Arm Label: Metronidazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metronidazole | Intervention Type: DRUG; Name: Azithromycin + Metronidazole; Assigned to Arm(s): Azithromycin + Metronidazole | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole
C: Arm Label: Antibiotic; Type: EXPERIMENTAL; Interventions: Drug: Ceftriaxone, Drug: Metronidazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo infusion | Intervention Type: DRUG; Name: Ceftriaxone; Assigned to Arm(s): Antibiotic | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Antibiotic | Intervention Type: OTHER; Name: Placebo infusion; Assigned to Arm(s): Placebo
D: Arm Label: Weekly SER-287, after Placebo Pre-Treat.; Type: EXPERIMENTAL; Interventions: Drug: SER-287, Drug: Placebo Pre-Treat | Arm Label: Daily placebo, after Placebo Pre-Treat.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Placebo Pre-Treat | Arm Label: Daily SER-287, after Vanco. Pre-Treat.; Type: EXPERIMENTAL; Interventions: Drug: SER-287, Drug: Vancomycin Pre-Treat | Arm Label: Weekly SER-287, after Vanco. Pre-Treat.; Type: EXPERIMENTAL; Interventions: Drug: SER-287, Drug: Vancomycin Pre-Treat | Intervention Type: DRUG; Name: SER-287; Assigned to Arm(s): Daily SER-287, after Vanco. Pre-Treat., Weekly SER-287, after Placebo Pre-Treat., Weekly SER-287, after Vanco. Pre-Treat. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Daily placebo, after Placebo Pre-Treat. | Intervention Type: DRUG; Name: Placebo Pre-Treat; Assigned to Arm(s): Daily placebo, after Placebo Pre-Treat., Weekly SER-287, after Placebo Pre-Treat. | Intervention Type: DRUG; Name: Vancomycin Pre-Treat; Assigned to Arm(s): Daily SER-287, after Vanco. Pre-Treat., Weekly SER-287, after Vanco. Pre-Treat.

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
Brief Summary: This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.


Options:
A: Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab 45/90 mg, Drug: placebo secukinumab | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg | Intervention Type: DRUG; Name: ustekinumab 45/90 mg; Assigned to Arm(s): Ustekinumab | Intervention Type: DRUG; Name: placebo secukinumab; Assigned to Arm(s): Ustekinumab
B: Arm Label: 80 mg ixekizumab Dosing Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 80 mg ixekizumab Dosing Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 80 mg ixekizumab Dosing Regimen 3; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 50 mg etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mg etanercept | Arm Label: Placebo for ixekizumab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 80 mg ixekizumab Dosing Regimen; Assigned to Arm(s): 80 mg ixekizumab Dosing Regimen 1, 80 mg ixekizumab Dosing Regimen 2, 80 mg ixekizumab Dosing Regimen 3 | Intervention Type: DRUG; Name: 50 mg etanercept; Assigned to Arm(s): 50 mg etanercept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo for ixekizumab
C: Arm Label: Etanercept; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept
D: Arm Label: Investigational drug - Dose 1; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Investigational drug - Dose 2; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACT-128800; Assigned to Arm(s): Investigational drug - Dose 1, Investigational drug - Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
Brief Summary: This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.


Options:
A: Arm Label: 80 mg ixekizumab Dosing Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 80 mg ixekizumab Dosing Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 80 mg ixekizumab Dosing Regimen 3; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 50 mg etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mg etanercept | Arm Label: Placebo for ixekizumab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 80 mg ixekizumab Dosing Regimen; Assigned to Arm(s): 80 mg ixekizumab Dosing Regimen 1, 80 mg ixekizumab Dosing Regimen 2, 80 mg ixekizumab Dosing Regimen 3 | Intervention Type: DRUG; Name: 50 mg etanercept; Assigned to Arm(s): 50 mg etanercept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo for ixekizumab
B: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The study compares the Veress needle technique, the Direct trocar insertion and the Open technique with each other, in terms of minor complications, in elective laparoscopic procedures for benign pathologies.


Options:
A: Arm Label: SILS appendectomy; Type: EXPERIMENTAL; Interventions: Procedure: SILS appendectomy | Arm Label: Conventional laparoscopic appendectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: conventional laparoscopic appendectomy | Intervention Type: PROCEDURE; Name: SILS appendectomy; Assigned to Arm(s): SILS appendectomy | Intervention Type: PROCEDURE; Name: conventional laparoscopic appendectomy; Assigned to Arm(s): Conventional laparoscopic appendectomy
B: Arm Label: Veress needle technique; Type: OTHER; Interventions: Procedure: Laparoscopy | Arm Label: Direct trocar technique; Type: OTHER; Interventions: Procedure: Laparoscopy | Arm Label: Open technique; Type: OTHER; Interventions: Procedure: laparoscopy | Intervention Type: PROCEDURE; Name: laparoscopy; Assigned to Arm(s): Open technique | Intervention Type: PROCEDURE; Name: Laparoscopy; Assigned to Arm(s): Veress needle technique | Intervention Type: PROCEDURE; Name: Laparoscopy; Assigned to Arm(s): Direct trocar technique | Intervention Type: PROCEDURE; Name: Laparoscopy; Assigned to Arm(s): Open technique
C: Arm Label: Single port laparoscopic device; Type: EXPERIMENTAL; Interventions: Device: Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa) | Arm Label: Four-port laparoscopic device; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Four port laparoscopic cholecystectomy surgery | Intervention Type: DEVICE; Name: Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa); Assigned to Arm(s): Single port laparoscopic device | Intervention Type: PROCEDURE; Name: Four port laparoscopic cholecystectomy surgery; Assigned to Arm(s): Four-port laparoscopic device
D: Arm Label: SIL-V; Type: ACTIVE_COMPARATOR; Interventions: Procedure: single incision laparoscopic varicocelectomy | Arm Label: CTL-V; Type: ACTIVE_COMPARATOR; Interventions: Procedure: conventional transperitoneal laparoscopic varicocelectomy | Intervention Type: PROCEDURE; Name: single incision laparoscopic varicocelectomy; Assigned to Arm(s): SIL-V | Intervention Type: PROCEDURE; Name: conventional transperitoneal laparoscopic varicocelectomy; Assigned to Arm(s): CTL-V

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Two Part Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2586881 in Patients With Acute Lung Injury
Brief Summary: This is an early phase (phase IIa), randomized, multi-center study in subjects with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). The purpose of this study is to investigate the safety of GSK2586881 and to determine what effects it has on people with Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).

The study has two parts: Part A will be an open-label investigation in five subjects. Part B will be a double-blind, placebo controlled investigation and will involve approximately 60 subjects.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Calfactant | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Room Air (placebo) | Intervention Type: DRUG; Name: Calfactant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Room Air (placebo); Assigned to Arm(s): 2
B: Arm Label: Part A; Type: EXPERIMENTAL; Interventions: Drug: Dose 1 GSK2586881, Drug: Dose 2 GSK2586881, Drug: Dose 3 GSK2586881, Drug: Dose 4 GSK2586881 | Arm Label: Part B; Type: EXPERIMENTAL; Interventions: Drug: Dose 3 GSK2586881, Drug: Placebo (saline) | Intervention Type: DRUG; Name: Dose 1 GSK2586881; Assigned to Arm(s): Part A | Intervention Type: DRUG; Name: Dose 2 GSK2586881; Assigned to Arm(s): Part A | Intervention Type: DRUG; Name: Dose 3 GSK2586881; Assigned to Arm(s): Part A, Part B | Intervention Type: DRUG; Name: Dose 4 GSK2586881; Assigned to Arm(s): Part A | Intervention Type: DRUG; Name: Placebo (saline); Assigned to Arm(s): Part B
C: Intervention Type: PROCEDURE; Name: pulmonary artery catheter; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: central venous catheter; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: fluid management; Assigned to Arm(s): N/A
D: Arm Label: No dexamethasone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
Brief Summary: This was a two-arm, open-label, randomized, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy with vemurafenib.


Options:
A: Arm Label: Temozolomide (TMZ); Type: EXPERIMENTAL; Interventions: Drug: Temozolomide (TMZ) | Arm Label: Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI); Type: EXPERIMENTAL; Interventions: Drug: Temozolomide (TMZ), Drug: Pegylated Interferon Alpha-2b (PGI) | Intervention Type: DRUG; Name: Temozolomide (TMZ); Assigned to Arm(s): Temozolomide (TMZ), Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI) | Intervention Type: DRUG; Name: Pegylated Interferon Alpha-2b (PGI); Assigned to Arm(s): Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI)
B: Arm Label: Dabrafenib plus Trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Arm Label: Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vemurafenib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib plus Trametinib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib plus Trametinib
C: Arm Label: Treatment (dabrafenib, trametinib, surgery); Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Other: Laboratory Biomarker Analysis, Procedure: Therapeutic Conventional Surgery, Drug: Trametinib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery)
D: Arm Label: Dostarlimab (TSR-042) (singly); Type: EXPERIMENTAL; Interventions: Drug: Dostarlimab (TSR-042) (singly) | Arm Label: Dostarlimab (TSR-042) and Cobolimab TSR-022 (combination); Type: EXPERIMENTAL; Interventions: Drug: Dostarlimab (TSR-042) and TSR-022 (combination) | Intervention Type: DRUG; Name: Dostarlimab (TSR-042) (singly); Assigned to Arm(s): Dostarlimab (TSR-042) (singly) | Intervention Type: DRUG; Name: Dostarlimab (TSR-042) and TSR-022 (combination); Assigned to Arm(s): Dostarlimab (TSR-042) and Cobolimab TSR-022 (combination)

Answer: B